APA (7th ed.) Citation

L, F., W, F., C, R., T, S., S, R., W, A., . . . C, B. (2026). Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: Phase I part of the GMALL-BLIVEN trial. Annals of hematology, 105(3), 109. https://doi.org/10.1007/s00277-026-06883-8

Chicago Style (17th ed.) Citation

L, Fransecky, et al. "Venetoclax and Blinatumomab for Adult Patients with Relapsed/refractory or MRD Positive Ph-negative B-cell Precursor ALL: Phase I Part of the GMALL-BLIVEN Trial." Annals of Hematology 105, no. 3 (2026): 109. https://doi.org/10.1007/s00277-026-06883-8.

MLA (9th ed.) Citation

L, Fransecky, et al. "Venetoclax and Blinatumomab for Adult Patients with Relapsed/refractory or MRD Positive Ph-negative B-cell Precursor ALL: Phase I Part of the GMALL-BLIVEN Trial." Annals of Hematology, vol. 105, no. 3, 2026, p. 109, https://doi.org/10.1007/s00277-026-06883-8.